ABSTRACT
Importance Spermine oxidase (SMOX) catalyzes the oxidation of spermine to spermidine. Observational studies have reported SMOX as a source of induced reactive oxygen species associated with cancer, implying that inhibition of SMOX could be a target for chemoprevention.
Objective To test the causality of SMOX levels with cancer risk using a Mendelian randomization analysis.
Design, Setting, and Participants We performed a GWAS of spermidine/spermine ratio, from blood of 534 infants, to identify genetic variants associated with regulation of SMOX activity. In two additional data sets of 262 newborns and 508 adults, we quantified SMOX gene expression using RNA-sequencing and performed expression and methylation QTL lookups. We then did a Mendelian randomization analysis by testing the association between the SMOX genetic instrument and various cancer types using GWAS summary statistics.
Main Outcomes and Measures Neuroblastoma, gastric, lung, breast, prostate, and colorectal cancers.
Results The GWAS of spermidine/spermine ratio identified a genome-wide significant locus (P=1.34×10−49) explaining 32% of the variance. The lead SNP rs1741315 was also associated with SMOX gene expression in newborns (P=8.48×10−28) and adults (P=2.748×10−8) explaining 37% and 6% of the variance, respectively. rs1741315 was not associated with neuroblastoma (OR=0.95; 95% CI:0.88, 1.03; P=0.18), gastric (OR=0.99; 95% CI:0.95, 1.03; P=0.54), lung (OR=0.97; 95% CI:0.94, 1.00; P=0.08), breast (OR=0.99; 95% CI:0.96, 1.02; P=0.47), prostate (OR=0.98; 95% CI:0.96, 1.00; P=0.05) nor colorectal cancer (OR=1.03; 95% CI:0.99, 1.07; P=0.10). A PheWAS of rs1741315 did not reveal any associations with risk factors of the cancers tested.
Conclusions and Relevance Genetic variation in the SMOX gene was strongly associated with SMOX activity in newborns, and less strongly in adults. Genetic down-regulation of SMOX was not significantly associated with lower odds of neuroblastoma, gastric, lung, breast, prostate and colorectal cancer. Further studies are needed to understand the effect of SMOX inhibition in relation to cancer risk.
Question Is SMOX causally associated with risk of cancer?
Findings In this Mendelian randomization study, genetically lower levels of SMOX were not associated with decreased risk of neuroblastoma, gastric, lung, breast, prostate and colorectal cancer.
Meaning These findings do not support a causal association between SMOX activity and risk of cancer, suggesting that ongoing efforts to identify SMOX inhibitors for chemoprevention may not be successful.
STRENGHTS AND LIMITATIONS
- Previous studies which examined SMOX activity and cancer risk were susceptible to recall bias, confounding and reverse causation, none of which are concerns of this Mendelian randomization study.
- Our genetic instrument explained a sizeable proportion of the variance of SMOX activity
- We used summary statistics from the largest meta-analyses of primary cancer GWAS to date.
- Elevated SMOX levels in cancer could also be due to environmental factors not captured by genetics.
- Our genetic instrument was developed based on normal range SMOX activity data, thus additional genetic variants might play a role in aberrant expression of this enzyme.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received partial support from the Danish Medical Reseach council, the Novo Nordisk Foundation and the Oak Foundation. It was conducted using the Danish National Biobank resource, supported by the Novo Nordisk Foundation. We would also like to acknowledge iPSYCH and The Lundbeck Foundation for their QTL validation datasets. The iPSYCH (The Lundbeck Foundation Initiative for Integrative Psychiatric Research) team acknowledges funding from The Lundbeck Foundation. This research has also been conducted using the UK Biobank Resource (project ID 31063) available from the Pan-UKB team. This work has also been supported by the European Regional Development Fund and the programme Mobilitas Pluss. This study was also funded by EU H2020 grant 692145, Estonian Research Council Grant PUT1660 and PRG687.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Danish Scientific Ethics Committee, the Danish Data Protection Agency and the Danish Neonatal Screening Biobank Steering Committee approved the PSYCH-twins study as well as the GWAS of metabolites in newborns. Usage of EGCUT RNA-seq dataset was approved by Estonian Committee on Bioethics and Human Research, protocol nr. 1.1-12/624, data extraction nr. N26.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available upon request.
